The GOG-240 trial established a new standard for recurrent or metastatic cervical cancer by adding which agent to platinum-based chemotherapy, significantly improving overall survival?
- A Pembrolizumab
- B Cetuximab
- C Bevacizumab ✓
- D Olaparib
Correct answer: C. Bevacizumab
Explanation
The GOG-240 trial demonstrated that adding bevacizumab (anti-VEGF monoclonal antibody) to paclitaxel–cisplatin or paclitaxel–topotecan significantly improved overall survival (17 months vs 13 months) in recurrent/metastatic cervical cancer. Pembrolizumab is approved for PD-L1-positive recurrent disease in later lines. Cetuximab and olaparib are not standard for cervical cancer.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.